Prenatal And Newborn Genetic Testing Market Forecast 2024-2033: Growth Rate, Drivers, And Trends

The Prenatal And Newborn Genetic Testing Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Prenatal And Newborn Genetic Testing Market:

https://www.thebusinessresearchcompany.com/report/prenatal-and-newborn-genetic-testing-global-market-report

According to The Business Research Company’s Prenatal And Newborn Genetic Testing Global Market Report 2024, The prenatal and newborn genetic testing market size has grown rapidly in recent years. It will grow from $5.87 billion in 2023 to $6.68 billion in 2024 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to improved non-invasive prenatal testing, increased maternal age, government support and healthcare policies, patient demand for early detection..

The prenatal and newborn genetic testing market size is expected to see rapid growth in the next few years. It will grow to $10.7 billion in 2028 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to expanded genetic test panels, increasing maternal health awareness, prenatal and newborn screening guidelines, rising focus on rare diseases, ethical and regulatory considerations.. Major trends in the forecast period include non-invasive prenatal testing (nipt), genome sequencing (wgs) and whole exome sequencing, integration of artificial intelligence (ai), preimplantation genetic testing (pgt), direct-to-consumer genetic testing..

Government initiatives and support for prenatal testing and newborn genetic screening are expected to propel the growth of the prenatal and newborn genetic testing markets going forward. Government initiatives refer to specific actions, programs, policies, or projects undertaken by a government at the local, regional, or national level to address a particular issue, achieve specific goals, or promote the well-being of its citizens. Government initiatives for prenatal and newborn genetic testing support the country’s people by helping identify genetic conditions or abnormalities in fetuses during pregnancy or in newborns shortly after birth. For instance, in June 2022, the Australian government allocated $1.3 million annually to the New South Wales (NSW) ( a state on the east coast of Australia) newborn screening program to offer free tests for severe combined immunodeficiency (SCID) and spinal muscular atrophy (SMA), including newborn genetic testing and screening, to all new babies in the state. The screening tests would be provided to around 100,000 babies each year, saving the lives of up to 13 newborns likely to have these genetic disorders. Therefore, government initiatives and support for prenatal testing and newborn genetic screening drive the prenatal and newborn genetic testing markets.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=13158&type=smp

The prenatal and newborn genetic testing market covered in this report is segmented –

1) By Product Type: Consumables, Instruments

2) By Screening: Non-Invasive Prenatal Testing, Chronic Villus Sampling, Amniocentesis, Maternal Serum Screening, Other Screenings

3) By Disease: Down Syndrome, Phenylketonuria, Cystic Fibrosis, Sickle Cell Anemia

4) By End User: Hospital, Maternity And Specialty Clinics, Diagnostic Centers

Major companies operating in the prenatal and newborn genetic testing markets are focusing on developing innovative screening tests, such as noninvasive prenatal screening tests, with improved accessibility and affordability to provide reliable services to customers. Noninvasive prenatal screening (NIPS), or noninvasive prenatal testing (NIPT), is a highly advanced and safe genetic screening method performed during pregnancy to assess the risk of specific fetal chromosomal abnormalities. For instance, in November 2022, Juno Diagnostics Inc., a US-based healthcare technology company, launched Juno Hazel, a noninvasive prenatal screening test that detects chromosomal aberrations and provides clinical content. The test uses a sample collection kit, eliminating the need for phlebotomy and improving accessibility. The company plans to offer educational resources and personalized genetic counseling support by partnering with physicians and genetic counselors.

The prenatal and newborn genetic testing market report table of contents includes:

Executive Summary
Prenatal And Newborn Genetic Testing Market Characteristics
Prenatal And Newborn Genetic Testing Market Trends And Strategies
Prenatal And Newborn Genetic Testing Market – Macro Economic Scenario
Global Prenatal And Newborn Genetic Testing Market Size and Growth

Global Prenatal And Newborn Genetic Testing Market Competitive Benchmarking
Global Prenatal And Newborn Genetic Testing Market Competitive Dashboard
Key Mergers And Acquisitions In The Prenatal And Newborn Genetic Testing Market
Prenatal And Newborn Genetic Testing Market Future Outlook and Potential Analysis
Appendix

Top Major Players: